Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial

[1]  A. Morice,et al.  Increased Propensity for Pneumonia with Fluticasone in Chronic Obstructive Pulmonary Disease. , 2017, American journal of respiratory and critical care medicine.

[2]  M. Miravitlles,et al.  A proposal for the withdrawal of inhaled corticosteroids in the clinical practice of chronic obstructive pulmonary disease , 2017, Respiratory Research.

[3]  C. Janson,et al.  Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD , 2017, International journal of chronic obstructive pulmonary disease.

[4]  D. Lomas,et al.  FULFIL Trial: Once‐Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease , 2017, American journal of respiratory and critical care medicine.

[5]  A. Morice,et al.  Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study , 2017, Lung.

[6]  J. Wedzicha,et al.  Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. , 2017, American journal of respiratory and critical care medicine.

[7]  Catherine Harvey,et al.  Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice. , 2016, The New England journal of medicine.

[8]  F. Martinez,et al.  Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial , 2016, The Lancet.

[9]  A. Tricco,et al.  Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis , 2015, BMJ Open.

[10]  A. Grossman,et al.  Adrenal suppression in patients taking inhaled glucocorticoids is highly prevalent and management can be guided by morning cortisol , 2015, European journal of endocrinology.

[11]  R. Dahl,et al.  Tiotropium HandiHaler® and Respimat® in COPD: a pooled safety analysis , 2015, International journal of chronic obstructive pulmonary disease.

[12]  N. Scichilone,et al.  Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS. , 2015, Pulmonary pharmacology & therapeutics.

[13]  F. Martinez,et al.  Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. , 2015, Annals of the American Thoracic Society.

[14]  P. Scanlon,et al.  Incident pneumonia and mortality in patients with chronic obstructive pulmonary disease. A double effect of inhaled corticosteroids? , 2015, American journal of respiratory and critical care medicine.

[15]  J. Dorca,et al.  Clinical Features, Etiology and Outcomes of Community-Acquired Pneumonia in Patients with Chronic Obstructive Pulmonary Disease , 2014, PloS one.

[16]  J. Kastelik,et al.  Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro–con perspective , 2014, British journal of clinical pharmacology.

[17]  R. DiSantostefano,et al.  Risk of Pneumonia with Inhaled Corticosteroid versus Long-Acting Bronchodilator Regimens in Chronic Obstructive Pulmonary Disease: A New-User Cohort Study , 2014, PloS one.

[18]  Kayleigh Kew,et al.  Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. , 2014, The Cochrane database of systematic reviews.

[19]  S. Suissa,et al.  Inhaled corticosteroids in COPD and the risk of serious pneumonia , 2013, Thorax.

[20]  B. Yawn,et al.  Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis , 2013, International journal of chronic obstructive pulmonary disease.

[21]  F. Martinez,et al.  Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. , 2013, The Lancet. Respiratory medicine.

[22]  D. Price,et al.  Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. , 2012, Primary care respiratory journal : journal of the General Practice Airways Group.

[23]  J. Wedzicha,et al.  The natural history of community-acquired pneumonia in COPD patients: a population database analysis. , 2012, Respiratory medicine.

[24]  A. Sharafkhaneh,et al.  Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. , 2012, Respiratory medicine.

[25]  K. Biggadike.  Fluticasone furoate/fluticasone propionate – different drugs with different properties , 2011, The clinical respiratory journal.

[26]  R. Cavallazzi,et al.  Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies , 2011, Thorax.

[27]  T. Seemungal,et al.  Reported pneumonia in patients with COPD: findings from the INSPIRE study. , 2011, Chest.

[28]  Sonal Singh,et al.  An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease , 2010, International journal of chronic obstructive pulmonary disease.

[29]  Peter J. Barnes,et al.  Inhaled Corticosteroids in COPD: A Controversy , 2010, Respiration.

[30]  M. Weatherall,et al.  Dose–response relationship of inhaled corticosteroids and cataracts: A systematic review and meta‐analysis , 2009, Respirology.

[31]  P. Jones,et al.  Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results , 2009, European Respiratory Journal.

[32]  Yoon K Loke,et al.  Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. , 2009, Archives of internal medicine.

[33]  David J Murphy,et al.  Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. , 2008, JAMA.

[34]  M. Decramer,et al.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.

[35]  T. Seemungal,et al.  The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. , 2008, American journal of respiratory and critical care medicine.

[36]  A. Gonzalez,et al.  Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. , 2007, American journal of respiratory and critical care medicine.

[37]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[38]  C. Lenfant,et al.  Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease , 2006 .

[39]  M. Skeans,et al.  Skin manifestations of inhaled corticosteroids in COPD patients: results from Lung Health Study II. , 2004, Chest.

[40]  M. Decramer,et al.  Clinical Trial Design Considerations in Assessing Long‐Term Functional Impacts of Tiotropium in COPD: The Uplift Trial , 2004, COPD.

[41]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[42]  S. Spencer,et al.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.